Skip to main content

Life Sciences is now live. See how →

Patent Examiner Amy Rose Hudson

Art Unit 1636 · Antisense, RNAi, Gene Therapy & Genome Editing · Tech Center 1600 · 396 applications filed 2021–2026

⚑ Hard · harder than 78% of examiners● Free examiner data

Amy Rose Hudson is a USPTO patent examiner in Art Unit 1636 (Antisense, RNAi, Gene Therapy & Genome Editing) with 396 applications from filing years 2021–2026. Examiner Hudson's allowance rate is 65.0%, below the 82.5% USPTO average for applications filed in the same years. The examiner ranks harder than 78% of examiners. In 2021, decided applications with an examiner interview were allowed 25.7 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Hard
harder than 78% of examiners
Easier78th percentileHarder
Allowance rate vs peers
Examiner Hudson65.0%
Art Units 1635 and 163657.5%
USPTO average82.5%
Allowance rate
65.0%
▼ USPTO avg 82.5%
Applications
396
filing years 2021–2026
First-action allowance
7.9%
patented with no rejection
Abandoned
22.5%
share of applications
Avg office actions
1.1
USPTO avg 1.3
Days to first OA
769
▲ USPTO 622
RCE rate
12.6%
USPTO 19.7%
Interview rate
9.6%
USPTO 27.3%

Examiner details

  • Art unit1636 · Antisense, RNAi, Gene Therapy & Genome Editing
  • Title / gradePrimary Patent Examiner · GS-14
  • Service22 years
  • PhoneOn each office action
  • In USPTO recordsHUDSON, AMY ROSE
Full signatory authority

Examiner Hudson can allow an application without a supervisory sign-off.

Examines (USPC classes)
514 · Drug, Bio-Affecting & Body Treating Compositions435 · Chemistry: Molecular Biology & Microbiology424 · Drug, Bio-Affecting & Body Treating Compositions

How to improve your odds with Examiner Hudson

  • The data favors an interview. Interviewed cases were allowed more often in both measured years, by 25.7 to 34.8 points.
  • Plan for the timeline. First office action averages 769 days vs the 622-day USPTO norm.
  • Expect a §112. Definiteness & disclosure is the most-issued rejection (199), and applicants overcame it 56.4% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 14.8 to 42.0 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§102 Novelty77 issued · 63.6% overcome
§103 Obviousness177 issued · 49.6% overcome
§112 Definiteness & disclosure199 issued · 56.4% overcome
How applicants traverse §112 rejections🔒 Members

Of the 42 winning responses to Examiner Hudson's §112 rejections that Boundly has classified, 33 (79%) amended the claims and argued, 6 argued without amending, and 3 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §112 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Hudson?

Draft your response with Examiner Hudson's record and Art Unit 1636's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Hudson.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202310.9%80.0%38.0%+42.0pp
202215.8%81.8%67.0%+14.8pp
202119.3%91.7%72.3%+19.4pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/622413Von Willebrand Factor (VWF)-Targeting Agents and Methods of Using the SamePatented1🔒 View
17/907833Chemically Modified Transfer RNA-Derived Small RNAs (tsRNAs) to Target Pathogenic BacteriaPatented2🔒 View
18/251720New Conjugated Nucleic Acid Molecules and Their UsesPatented1🔒 View
18/194203Angiotensinogen-Modulating Compositions and Methods of Use ThereofAbandoned2🔒 View
See all 396 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1636 technology

Antisense & RNAi therapeuticsGene therapy & nucleic acid drugsCRISPR & genome editingNucleic acid assays & screeningTop CPC C12N · A61K · C07K
About this examiner. Amy Rose Hudson examines in Art Unit 1636 (Antisense, RNAi, Gene Therapy & Genome Editing, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Amy Rose Hudson's allowance rate?
Examiner Hudson's allowance rate is 65.0%, compared with 82.5% across the USPTO and 57.5% in Art Units 1635 and 1636 for applications filed in the same years. That rate ranks Examiner Hudson harder than 78% of examiners.
Is Examiner Hudson a hard examiner?
Somewhat. Examiner Hudson ranks harder than 78% of examiners, in the 78th difficulty percentile (hard). Examiner Hudson has a 65.0% allowance rate versus 82.5% across the USPTO and 57.5% in Art Units 1635 and 1636, 1.1 office actions per application versus 1.3, and an RCE rate of 12.6% versus 19.7% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Hudson?
In this examiner's record, yes. Decided applications with an interview were allowed more often in both measured years, by 25.7 to 34.8 percentage points. In 2021, 94.7% of decided applications with an interview were allowed, versus 69.0% of those without.
What is Examiner Hudson's most common rejection?
§112 definiteness & disclosure, issued 199 times in the data. Applicants overcame it 56.4% of the time. Of the 42 winning responses Boundly has classified, 33 amended the claims and argued.
Is an RCE worth filing with Examiner Hudson?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in each of the 3 measured years, by 14.8 to 42.0 percentage points. In 2021, 91.7% of decided applications with an RCE were allowed, versus 72.3% of those without one.
How long until the first office action from Examiner Hudson?
About 769 days on average, versus 622 days across the USPTO for applications filed in the same years.

Put Examiner Hudson's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Amy Rose Hudson, or see an error? Request a correction.